Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years

Highlights ► We modeled the impact of vaccination on risk of pneumococcal disease in older US adults. ► Model projections suggest that use of PCV13 (vs. PPSV23): (i) without revaccination, would reduce cases of disease and lower total costs; and (ii) with revaccination every 5–10 years, would result...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 30; no. 36; pp. 5437 - 5444
Main Authors Weycker, Derek, Sato, Reiko, Strutton, David, Edelsberg, John, Atwood, Mark, Jackson, Lisa A
Format Journal Article
LanguageEnglish
Published Netherlands 03.08.2012
Subjects
Aged
Aged, 80 and over
Allergy and Immunology
Computer Simulation
Humans
Markov Chains
Middle Aged
Pneumococcal Infections - economics
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - economics
Pneumococcal Vaccines - immunology
Public Health - economics
United States
United States
Pneumococcal vaccines
Pneumonia
Pneumococcal infections
Streptococcus pneumoniae
Online AccessGet full text
ISSN0264-410X
1873-2518
1873-2518
DOI10.1016/j.vaccine.2012.05.076

Cover

More Information
Summary:Highlights ► We modeled the impact of vaccination on risk of pneumococcal disease in older US adults. ► Model projections suggest that use of PCV13 (vs. PPSV23): (i) without revaccination, would reduce cases of disease and lower total costs; and (ii) with revaccination every 5–10 years, would result in the fewest cases and lowest costs. ► Projected impact of PCV13 in older US adults is favorable vs. current practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2012.05.076